Interim Results for the six months ended 31 December 2021
03 mars 2022 07h00 HE
|
Allergy Therapeutics
Allergy Therapeutics plc(“Allergy Therapeutics” or the “Company” or the “Group”) Interim Results for the six months ended 31 December 2021 ~ US readiness plan underway including two...
Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut
26 janv. 2022 07h00 HE
|
Allergy Therapeutics
Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut Paves...
Allergy Therapeutics announces positive top line results from G309 exploratory field trial to evaluate efficacy and safety of Grass MATA MPL
25 oct. 2021 07h00 HE
|
Allergy Therapeutics
Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces positive top line results from G309 exploratory field trial to evaluate efficacy and safety...
Preliminary Results for the Year ended 30 June 2021
23 sept. 2021 07h00 HE
|
Allergy Therapeutics
Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Preliminary Results for the Year ended 30 June 2021 Record pre-R&D operating profit ahead of market expectations...
Trading update
24 juin 2021 07h00 HE
|
Allergy Therapeutics
Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Trading update Operating profit strong and expected to be well ahead of market expectationsExpenses for 2021 significantly...
Allergy Therapeutics plc Preliminary Results for the year ended 30 June 2020
23 sept. 2020 07h00 HE
|
Allergy Therapeutics
Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Preliminary Results for the year ended 30 June 2020 Record level of pre R&D operating profit supported by robust sales...
Allergy Therapeutics secures virus-like particle (“VLP”) technology platform to broaden vaccine pipeline through licensing agreements with Saiba AG and DeepVax GmbH
03 sept. 2020 07h00 HE
|
Allergy Therapeutics
Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”), Saiba AG(“Saiba”) and DeepVax GmbH (“DeepVax”) Allergy Therapeutics secures virus-like particle (“VLP”) technology platform to...
Allergy Therapeutics Interim Results for the six months ended 31 December 2019
04 mars 2020 07h00 HE
|
Allergy Therapeutics
Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”)Interim Results for the six months ended 31 December 2019 Record level of operating profit pre R&D supported by strong...
Allergy Therapeutics publishes encouraging new data for peanut allergy vaccine candidate in The Journal of Allergy and Clinical Immunology
29 janv. 2020 07h01 HE
|
Allergy Therapeutics
Allergy Therapeutics plc (“Allergy Therapeutics” or the “Group”) Allergy Therapeutics publishes encouraging new data for peanut allergy...
Allergy Therapeutics plc - Successful litigation settlement relating to PQ Grass Phase II Trial
27 juin 2019 10h47 HE
|
Allergy Therapeutics
Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Successful litigation settlement relating to PQ Grass Phase II Trial 27 June 2019 Allergy Therapeutics plc (AIM: AGY), the...